Perspective Therapeutics Presents Updated Interim Data from its Ongoing Phase 1/2a Clinical Trial of [212Pb]VMT-a-NET at the ESMO Congress 2025
Perspective Therapeutics, Inc. (CATX)
Company Research
Source: GlobeNewswire
Updated interim results with an additional ~19 weeks of follow-up since the prior update [212Pb]VMT-a-NET continues to be well-tolerated Objective Response Rate of 44% (7 of 16 patients) in Cohort 2 with SSTR2 expression in all tumors at median follow-up of 41 weeks; 14 of the 16 patients remain free from progression and on studyInitial efficacy data pending for an additional 23 patients in Cohort 2 and 8 patients in Cohort 3, expected during 2026Perspective will hold a conference call on Monday, October 20, 2025 at 8:30 am ET SEATTLE, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, announced that updated interim results from its ongoing Phase 1/2a clinical trial (NCT05636618) of [212Pb]VMT-a-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs) we
Show less
Read more
Impact Snapshot
Event Time:
CATX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CATX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CATX alerts
High impacting Perspective Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CATX
News
- Perspective Therapeutics Announces Acceptance of VMT-a-NET Data for Presentation at the ASCO Gastrointestinal Cancers SymposiumGlobeNewswire
- Perspective Therapeutics (NASDAQ:CATX) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating and a $12.00 price target on the stock.MarketBeat
- Perspective Therapeutics (NASDAQ:CATX) had its price target lowered by analysts at B. Riley from $12.00 to $11.00. They now have a "buy" rating on the stock.MarketBeat
- Perspective Therapeutics (NASDAQ:CATX) had its price target lowered by analysts at UBS Group AG from $18.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- Perspective Therapeutics to Participate in Upcoming December ConferencesGlobeNewswire
CATX
Earnings
- 11/10/25 - Miss
CATX
Sec Filings
- 12/1/25 - Form 8-K
- 11/17/25 - Form 4
- 11/14/25 - Form 4
- CATX's page on the SEC website